Confined or spread disease-Spread with distant metastasis Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread with distant metastasis Posts on Medivizor

Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer

Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer

Posted by on Feb 26, 2021 in Melanoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of stereotactic ablative radiation therapy (SABR) in the treatment of patients with oligometastatic (few metastases) cancer. The data showed that the use of SABR in these patients was associated with high overall survival and low toxicity. Some background Oligometastatic cancer (OMC)...

Read More

Is radiosurgery in combination with other cancer therapies safe in patients with brain metastasis?

Is radiosurgery in combination with other cancer therapies safe in patients with brain metastasis?

Posted by on Jan 31, 2021 in Breast cancer | 0 comments

In a nutshell The aim of this study was to evaluate the safety of giving stereotactic radiosurgery (SRS) at the same time as other cancer treatments for patients who have brain metastasis. The study found that SRS given in combination with chemotherapy, immunotherapy, or targeted therapy was safe with low levels of side effects. Some background The...

Read More

Is radiosurgery in combination with other cancer therapies safe in patients with brain metastasis?

Is radiosurgery in combination with other cancer therapies safe in patients with brain metastasis?

Posted by on Jan 31, 2021 in Melanoma | 0 comments

In a nutshell The aim of this study was to evaluate the safety of giving stereotactic radiosurgery (SRS) at the same time as other cancer treatments for patients who have brain metastasis. The study found that SRS given in combination with chemotherapy, immunotherapy, or targeted therapy was safe with low levels of side effects. Some background...

Read More

FOLFOXIRI-bevacizumab or FOLFOX-panitumumab for the treatment of left-sided metastatic colorectal cancer without RAS/BRAF mutations.

FOLFOXIRI-bevacizumab or FOLFOX-panitumumab for the treatment of left-sided metastatic colorectal cancer without RAS/BRAF mutations.

Posted by on Jan 24, 2021 in Colorectal cancer | 0 comments

In a nutshell This study compared the use of chemotherapy and bevacizumab (Avastin) or panitumumab (Vectibix) for the treatment of left-sided metastatic colorectal cancer (mCRC) without BRAF/RAS mutations (permanent changes in genes). The study found that both treatment options are effective for these patients.  Some background Patients who...

Read More

Bevacizumab combined with first-line chemotherapy for metastatic colorectal cancer in a real-world setting

Bevacizumab combined with first-line chemotherapy for metastatic colorectal cancer in a real-world setting

Posted by on Jan 19, 2021 in Colorectal cancer | 0 comments

In a nutshell This article looked at the effectiveness of bevacizumab (Avastin) with chemotherapy for metastatic colorectal cancer (mCRC) in a real-world setting. The authors found that the addition of bevacizumab to chemotherapy regimens provides survival benefits in patients who cannot undergo curative local treatment. Some background...

Read More

Colorectal cancer treatment with regorafenib and trifluridine/tipiracil: A comparison

Colorectal cancer treatment with regorafenib and trifluridine/tipiracil: A comparison

Posted by on Jan 10, 2021 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of regorafenib (Stivarga), trifluridine/tipiracil (TFTP; Lonsurf), and combinations of these drugs in the treatment of patients with inoperable colorectal cancer. Researchers suggested that a combination of TFTP and regorafenib is associated with longer survival and fewer side effects. Some...

Read More

Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?

Does immune checkpoint therapy and radiotherapy combination improve response in treating brain metastasis from non-small cell lung cancer and melanoma?

Posted by on Dec 30, 2020 in Melanoma | 0 comments

In a nutshell The study evaluated the timing of radiotherapy (RT) and immune-checkpoint therapy (ICT) on the outcomes of patients with brain metastasis (BrM) resulting from melanoma and non-small cell lung cancer (NSCLC). The authors found that RT and ICT given at the same time may improve response and delay recurrence in these patients. Some...

Read More

Comparing the outcomes of utidelone plus capecitabine versus capecitabine alone in patients with previously treated resistant metastatic breast cancer

Comparing the outcomes of utidelone plus capecitabine versus capecitabine alone in patients with previously treated resistant metastatic breast cancer

Posted by on Dec 26, 2020 in Breast cancer | 0 comments

In a nutshell The study compared outcomes of utidelone plus capecitabine (Xeloda) versus capecitabine (C) alone in previously treated patients with anthracycline- and taxane-resistant metastatic breast cancer (MBC). The authors found that this combination improved survival compared to C alone in such patients. Some background...

Read More